XBiotech (NASDAQ:XBIT) Shares Pass Above 50-Day Moving Average – Time to Sell?

XBiotech Inc. (NASDAQ:XBIT)’s share price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $3.37 and traded as high as $3.46. XBiotech shares last traded at $3.30, with a volume of 21,241 shares.

XBiotech Price Performance

The company has a fifty day simple moving average of $3.37 and a 200-day simple moving average of $5.42. The company has a market cap of $100.61 million, a P/E ratio of -3.06 and a beta of 1.25.

XBiotech (NASDAQ:XBIT) last announced its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Deutsche Bank AG acquired a new stake in shares of XBiotech in the fourth quarter worth $120,000. Northern Trust Corp boosted its position in XBiotech by 15.2% during the 4th quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company’s stock worth $835,000 after acquiring an additional 27,909 shares during the period. BNP Paribas Financial Markets grew its stake in XBiotech by 184.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 40,040 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 25,987 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of XBiotech by 5.1% in the 3rd quarter. Geode Capital Management LLC now owns 452,264 shares of the biopharmaceutical company’s stock valued at $3,496,000 after purchasing an additional 22,059 shares during the period. Finally, State Street Corp lifted its position in shares of XBiotech by 10.7% in the third quarter. State Street Corp now owns 224,595 shares of the biopharmaceutical company’s stock worth $1,736,000 after purchasing an additional 21,752 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors and hedge funds.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.